Shipped in a discreet, unmarked envelope with all required documents enclosed.
Product Sheet
Active Ingredient(s)
Fluticasone propionate, Salmeterol xinafoate
Reference Brand
Seretide
Product Origin
Generic Product
Reference Manufacturer
GlaxoSmithKline
Product Form
Inhaler, Dry Powder Inhaler
Regulatory Classification
Rx
Primary Category
Respiratory Health
Product Category
Corticosteroid, Beta-2 Agonist
Pharmacological Class
Inhaled Bronchodilators
Clinical Indications
Asthma, Chronic Obstructive Pulmonary Disease
Manufacturer Description
This combination is designed to manage chronic respiratory airway conditions, helping to alleviate inflammation and bronchodilation for improved lung function and respiratory comfort.
Mechanism of Action
Fluticasone acts as an anti-inflammatory corticosteroid to reduce airway swelling, while salmeterol acts as a long-acting beta-2 agonist to relax bronchial muscles. Together, they provide sustained airway patency for patients with long-term breathing management needs.
Route of Administration
Inhalation
Onset Time
15-30 minutes
Duration
12 hours
Contraindications
Acute asthma attacks, Severe milk protein allergy
Severe Adverse Events
Increased pneumonia risk, Adrenal suppression, Bone density reduction
Common Side Effects
Throat irritation, Hoarseness, Dry mouth
Uncommon Side Effects
Tremor, Headache, Palpitations
Drug Interactions
Ketoconazole, Ritonavir, Beta-blockers
Pregnancy Safety Warnings
Use only if the potential benefit outweighs the risk to the fetus.
Age Restrictions
Consult a healthcare provider for pediatric use.
Storage Guidelines
Store at room temperature in a dry place.
Related Products
Budesonide, Formoterol
Information associated with Fluticasone with Salmeterol is curated and periodically reviewed using established medical references and prescribing guidelines. Content is intended for general awareness and should be verified with a licensed healthcare professional before use.
